Quantcast

Latest Therapies under investigation for multiple sclerosis Stories

2008-09-02 12:00:34

Research and Markets (http://www.researchandmarkets.com/research/f0d42d/cns_drug_discoveri) has announced the addition of the "CNS Drug Discoveries: Multiple Sclerosis Chapter" report to their offering. This chapter of CNS Drug Discoveries focuses on the multiple sclerosis market. With the launch of up to 12 new disease-modifying agents, three vaccines and one novel drug designed to treat the symptoms of multiple sclerosis (MS) and improve quality of life, the MS market is in an...

2008-08-29 06:00:55

Biogen Idec has completed enrollment in the Assurance trial, a long-term follow-up study which will assess up to 15 years of Avonex treatment in an effort to provide detailed data on the long-term efficacy of the drug. Assurance is a multi-center, open-label follow-up study of patients with relapsing multiple sclerosis (MS) treated with Avonex or placebo for at least two years in the Phase III pivotal trial. In the trial, 136 of a possible 172 patients were identified for this study at...

2008-07-30 12:00:21

CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases. PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially...

2008-07-16 12:01:29

CAMBRIDGE, Mass., July 16 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced that it has completed a second close of $8.9 million of its Series D preferred stock offering with its investor syndicate led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, and its Chairman of the Board. The proceeds of the financing are primarily being used to advance clinical development of Peptimmune's...

2008-07-16 09:01:19

Teva Pharmaceutical Industries and Active Biotech have announced that patients are being enrolled for the Bravo Phase III pivotal trial. Bravo is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex. The Bravo trial, which was initiated in April, 2008, aims to enroll approximately 1,200...

2008-07-15 12:01:01

Theravance has announced the positive results from a Phase I study designed to assess the safety, tolerability and pharmacokinetics of an investigational inhaled long-acting muscarinic antagonist, GSK1160724/TD-4208, for the treatment of chronic obstructive pulmonary disease. In the study, TD-4208 was generally well tolerated with a similar incidence of adverse events to placebo and there was no significant increase in heart rate or evidence of dry mouth. Abnormal taste was reported at the...

2008-07-09 06:00:38

Opexa Therapeutics has announced that the data safety monitoring board overseeing the on-going Phase IIb clinical study of Tovaxin has recommended that the trial continue unmodified. This positive recommendation follows a regularly scheduled meeting of the data safety monitoring board (DSMB) in June 2008, and is based upon an evaluation of clinical, magnetic resonance imaging (MRI) and safety data that had been recorded for all patients to date. The Terms trial is nearing completion and...

2008-07-07 09:01:02

Teva Pharmaceutical Industries has reported results from a Phase III study designed to assess the efficacy, safety and tolerability of glatiramer acetate 40mg as compared to the approved Copaxone 20mg in the treatment of relapsing-remitting multiple sclerosis. The 40mg dose did not demonstrate increased efficacy in reducing the relapse rate; however, the higher dose maintained the favorable safety and tolerability profile of Copaxone 20mg. Approximately 70-80% (78%) of Copaxone 20mg...

2008-07-07 03:00:34

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced top-line results from a Phase III study designed to assess the efficacy, safety and tolerability of glatiramer acetate (GA) 40mg as compared to the approved COPAXONE(R) 20mg in the treatment of relapsing-remitting multiple sclerosis (RRMS). The 40mg dose did not demonstrate increased efficacy in reducing the relapse rate; however, the higher dose maintained the favorable safety and tolerability profile of COPAXONE(R) 20mg....

2008-07-01 09:00:12

arGentis Pharmaceuticals, LLC announced today that it has filed a patent application for Nucleic Acid Sequences highly associated with the inability of oral immune tolerance to be induced in some systemic sclerosis (SSc) patients. As explained in the patent application, the identified sequences predict which patients can respond to ARG201, an immunotherapy that induces oral immune tolerance in patients with Late Phase diffuse cutaneous systemic sclerosis. Results from patient DNA samples...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related